Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Celularity Inc (CELU)

Celularity Inc (CELU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,047
  • Shares Outstanding, K 28,838
  • Annual Sales, $ 54,220 K
  • Annual Income, $ -57,890 K
  • EBIT $ -47 M
  • EBITDA $ -39 M
  • 60-Month Beta 0.79
  • Price/Sales 0.74
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 405.38% (-88.37%)
  • Historical Volatility 72.08%
  • IV Percentile 90%
  • IV Rank 38.82%
  • IV High 900.41% on 12/23/25
  • IV Low 91.28% on 09/08/25
  • Expected Move (DTE 14) 1.1475 (95.63%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 32
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 556
  • Open Int (30-Day) 1,209
  • Expected Range 0.0525 to 2.3475

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -2.20
  • Growth Rate Est. (year over year) +45,509.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0701 +12.14%
on 03/03/26
1.5100 -20.53%
on 02/18/26
+0.0300 (+2.56%)
since 02/05/26
3-Month
1.0100 +18.81%
on 12/31/25
1.9800 -39.39%
on 12/08/25
-0.7800 (-39.39%)
since 12/05/25
52-Week
1.0100 +18.81%
on 12/31/25
4.3500 -72.41%
on 07/22/25
-0.1700 (-12.41%)
since 03/05/25

Most Recent Stories

More News
Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses

FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2...

CELU : 1.2000 (-4.00%)
CELUW : 0.0087 (+17.57%)
Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations

FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases,...

CELU : 1.2000 (-4.00%)
CELUW : 0.0087 (+17.57%)
Celularity Announces Closing of Financing Transactions

FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases,...

CELU : 1.2000 (-4.00%)
CELUW : 0.0087 (+17.57%)
Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

The contemplated financing transactions would provide up to $12 Million in capital to support Celularity’s strategic priorities around longevity and preservation of human performance. FLORHAM PARK,...

CELU : 1.2000 (-4.00%)
CELUW : 0.0087 (+17.57%)
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care

FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases,...

CELU : 1.2000 (-4.00%)
CELUW : 0.0087 (+17.57%)
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease

First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery disease Celularity PDA-002 achieved durable wound healing with just two intramuscular doses As a qualified...

CELU : 1.2000 (-4.00%)
CELUW : 0.0087 (+17.57%)
Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance

Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance...

CELU : 1.2000 (-4.00%)
CELUW : 0.0087 (+17.57%)
Celularity Receives Nasdaq Notice Regarding Form 10-Q

FLORHAM PARK, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on addressing age-related...

CELU : 1.2000 (-4.00%)
CELUW : 0.0087 (+17.57%)
Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt

Retired all principal and accrued interest owed its two senior secured lenders, Resorts World Inc. Pte. Ltd., or RWI, and C.V. Starr and Co., Inc., eliminating all senior secured debt from its balance...

CELU : 1.2000 (-4.00%)
CELUW : 0.0087 (+17.57%)
Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

CELU : 1.2000 (-4.00%)
CELUW : 0.0087 (+17.57%)

Business Summary

Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR and mesenchymal-like adherent stromal cells...

See More

Key Turning Points

3rd Resistance Point 1.3000
2nd Resistance Point 1.2800
1st Resistance Point 1.2400
Last Price 1.2000
1st Support Level 1.1800
2nd Support Level 1.1600
3rd Support Level 1.1200

See More

52-Week High 4.3500
Fibonacci 61.8% 3.0741
Fibonacci 50% 2.6800
Fibonacci 38.2% 2.2859
Last Price 1.2000
52-Week Low 1.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar